Non-Severe COVID-19 Complicated by Deep Vein Thrombosis (DVT)

Authors

  • Wulyo Rajabto Faculty of Medicine, Universitas Indonesia - Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Jakarta https://orcid.org/0000-0002-8231-418X
  • Dimas Priantono Faculty of Medicine, Universitas Indonesia - Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Jakarta https://orcid.org/0000-0003-0348-7902

DOI:

https://doi.org/10.36497/jri.v44i2.263

Keywords:

anticoagulant, DVT, non-severe COVID-19, VTE

Abstract

Background: Coronavirus Disease 2019 (COVID-19) displays various symptoms ranging from asymptomatic to life-threatening. Patients may present with typical respiratory infections or atypical symptoms. Non-severe COVID-19 encompasses mild and moderate cases, characterized by the absence of criteria for severe or critical illness, with mild cases not showing evidence of viral pneumonia or hypoxia and moderate cases maintaining SpO2 levels of at least 90% on room air.

Case: We presented a COVID-19 case with the chief complaint of unilateral leg swelling. A 48-year-old male was admitted with the chief complaint of cramps and swelling of the left leg. He had a history of fever, cough, nausea, and vomiting. Laboratory studies showed elevated D-dimer. Doppler ultrasound shows signs of both proximal and distal deep vein thrombosis.  CT pulmonary angiography excluded pulmonary embolism while the lung window image supported the diagnosis of COVID-19 pneumonia. Polymerase chain reaction (PCR) obtained from nasopharyngeal and oropharyngeal swabs confirmed COVID-19 infection.

Discussion: We treated the patient with parenteral anticoagulation followed by direct oral anticoagulant upon discharge. The swelling improved as well as the patient’s clinical status. Thromboembolic complications have been credited as the culprit of high mortality in COVID-19. Systemic activation of coagulation in pulmonary and peripheral circulation contributed to life-threatening thrombotic complications. Our patient presented with COVID-19-associated proximal and distal DVT without pulmonary embolism.

Conclusion: Prompt diagnosis of COVID-19 infection and acute DVT improves patient care. The hallmark of the management of VTE in COVID-19 patients is treatment with therapeutic dose parenteral anticoagulation followed by oral anticoagulant.

Downloads

Download data is not yet available.

References

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

World Health Organization. Clinical management of COVID-19: Living guideline, 18 August 2023 [Internet]. World Health Organization; 2023. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.2

Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia, Ikatan Dokter Anak Indonesia. Pedoman tatalaksana COVID-19. Pedoman tatalaksana COVID-19 edisi 4. Indonesia; 2022.

Hajra A, Mathai SV, Ball S, Bandyopadhyay D, Veyseh M, Chakraborty S, et al. Management of thrombotic complications in COVID-19: An update. Drugs. 2020;80(15):1553–62.

Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with Coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158(3):1143–63.

Hirsh J, Lee AYY. How we diagnose and treat deep vein thrombosis. Blood. 2002;99(9):3102–10.

Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. J Intensive Care. 2020;8:49.

Tal S, Spectre G, Kornowski R, Perl L. Venous thromboembolism complicated with COVID-19: What do we know so far? Acta Haematol. 2020;143(5):417–24.

Angchaisuksiri P. Venous thromboembolism in Asia--an unrecognised and under-treated problem? Thromb Haemost. 2011;106(4):585–90.

Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action. Br J Haematol. 2020;189(5):846–7.

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.

Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6.

Carfora V, Spiniello G, Ricciolino R, Di Mauro M, Migliaccio MG, Mottola FF, et al. Anticoagulant treatment in COVID-19: A narrative review. J Thromb Thrombolysis. 2021;51(3):642–8.

Dronkers CEA, Tan M, Mol GC, Iglesias Del Sol A, Van De Ree MA, Huisman M V., et al. Evaluation of the new simple and objective clinical decision rule “I-DVT” in patients with clinically suspected acute deep vein thrombosis. Thromb Res. 2016;141:112–8.

Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and Standardization Committee Communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859–65.

Downloads

Additional Files

Published

2024-04-30

Issue

Section

Case Report

Similar Articles

1-10 of 76

You may also start an advanced similarity search for this article.